Abstract

Interferon lambda-2 (IL28A) has a wide antiviral effect with fewer side-effects. Autophagy is a host mechanism to maintain intracellular homeostasis and defends invasion of pathogenic microorganisms. HCV NS5A can disable host defense systems to support HCV replication. Thus, molecular mechanism of interaction among interferon lambda, autophagy, and HCV was concerned and explored in this study. We report that HCV NS5A activated an incomplete autophagy by promoting the autophagic ubiquitylation-like enzymes ATG3, ATG5, ATG7, ATG10, and autophagosome maker LC3B, but blocked autophagy flux; IL28A bound to NS5A at NS5A-ISDR region, and degraded HCV-NS5A by promoting autolysosome formations in HepG2 cells. A software prediction of IL28A protein conformation indicated a potential structure of IL28A homotetramer; the first α-helix of IL28A locates in the interfaces among the four IL28A chains to maintain IL28A homotetrameric conformation. Co-IP and cell immunofluorescence experiments with sequential deletion mutants demonstrate that IL28A preferred a homotetramer conformation to a monomer in the cells; the IL28A homotetramer is positively correlated with autolysosomal degradation of HCV NS5A and the other HCV proteins. Summarily, the first α-helix of IL28A protein is the key domain for maintaining IL28A homotetramer which is required for promoting formation of autolysosomes and degradation of HCV proteins in vitro.

Highlights

  • Hepatitis C virus (HCV) is an important human pathogen

  • Respecting that HCV NS5A has a critical role in HCV genome replication through docking the HCV replication complex to the autophagosome membrane[36,37], we examined whether the HCV NS5A protein functions in formation of autophagosomes

  • We tested autophagy-related proteins and heterodimer that are involved in the two autophagy ubiquitination systems: ATG3, ATG5-ATG12, ATG7, and ATG10; HCV NS5A protein induced higher expression of the four proteins than the mock group (Fig. 1a)

Read more

Summary

Introduction

Hepatitis C virus (HCV) is an important human pathogen. HCV infection incidence has increased globally and its complication remains a problem for a long time. Several medicines directed against HCV proteins (direct-acting antiviral agents, DAAs) have been in clinical use, including NS3/4A-targeted Telaprevir and Simeprevir, NS5A-targeted Daclatasvir and Ledipasvir, and NS5B-targeted Sofosbuvir, which have greatly improved treatment of HCV infection. Host factors with anti-virus property have been got Official journal of the Cell Death Differentiation Association. Ma et al Cell Death and Disease (2020)11:200 have been shown to inhibit the replication of a wide variety of viruses, such as VSV, EMCV, HBV, HCV and human cytomegaloviruses in vitro and vaccinia virus and herpes simplex virus type 2 in vivo[11,12]. IL28A was studied in this work as a representative member of the type III interferon family

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call